These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32869255)

  • 1. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
    Deng T; Duan X; He Z; Zhao Z; Zeng G
    Urol J; 2020 Aug; 18(2):144-150. PubMed ID: 32869255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of Association between 5α-Reductase Inhibitors and Depression.
    Dyson TE; Cantrell MA; Lund BC
    J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis.
    Wang J; Zhao S; Luo L; Li E; Li X; Zhao Z
    Int Braz J Urol; 2018; 44(5):865-873. PubMed ID: 29697934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
    Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
    JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
    Fang Q; Chen P; Du N; Nandakumar KS
    Clin Breast Cancer; 2019 Oct; 19(5):e624-e636. PubMed ID: 31126837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of rhabdomyolysis from 5-α reductase inhibitors.
    Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
    Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis.
    Zhang JJ; Shi X; Wu T; Zhang MD; Tang J; Yin GM; Long Z; He LY; Qi L; Wang L
    Asian J Androl; 2022; 24(4):390-397. PubMed ID: 34747724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
    Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
    World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Alpha-Reductase Inhibitors and Combination Therapy.
    Füllhase C; Schneider MP
    Urol Clin North Am; 2016 Aug; 43(3):325-36. PubMed ID: 27476125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
    Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
    JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
    Yuan JQ; Mao C; Wong SY; Yang ZY; Fu XH; Dai XY; Tang JL
    Medicine (Baltimore); 2015 Jul; 94(27):e974. PubMed ID: 26166130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction.
    Andrade C
    J Clin Psychiatry; 2018 Nov; 79(6):. PubMed ID: 30549493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.